Bachem (BANB.SW) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BANB.SW · Stock Price

CHF 81.85+31.20 (+61.60%)

Market Cap: $7.8B

Historical price data

Market Cap: $7.8BPipeline: 1 drugPatents: 1Founded: 1971Employees: 1000+HQ: Bubendorf, Switzerland

Sector Ranking#6 in Proteomics & Protein Engineering #7 in RNA Therapeutics (non-mRNA)

Overview

Bachem is a publicly traded, Swiss-based CDMO with a market capitalization of ~$4.68B, specializing in the complex manufacturing of peptide and oligonucleotide APIs. Its mission is to be the world's most trusted and reliable partner in the TIDES space, aiming for sales north of CHF 1 billion. The company's strategy is built on five pillars: People & Culture, Innovation & Technology, Sustainability, Customer Centricity, and Operational Excellence, supported by continuous capacity expansion and technological investment.

Metabolic DisordersOncologyCardiovascularCNSRare Genetic Diseases

Technology Platform

Integrated development and GMP manufacturing platform for complex peptides and oligonucleotides (TIDES), encompassing solid-phase/solution-phase synthesis, process scale-up, and comprehensive analytical support.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
ghrelin	Advanced Cancer	Phase 1/2

Funding History

1

Total raised:$110M

IPO$110MUndisclosedOct 6, 1998

Opportunities

The rapid growth of the oligonucleotide therapeutics market presents a major expansion opportunity.

Bachem's strategic investments in oligo capacity position it to capture significant share in this high-growth segment, complementing its dominant peptide franchise.

Risk Factors

Key risks include dependency on client pipeline success, significant capital expenditure requirements for capacity expansion, and increasing competitive pressure, particularly in the oligonucleotide CDMO space from larger, diversified players.

Competitive Landscape

Bachem competes in a specialized niche against pure-play peptide CDMOs like PolyPeptide Group and diversified giants like Thermo Fisher and Lonza expanding into oligonucleotides. Its deep peptide heritage, integrated TIDES offering, and reputation for quality are primary differentiators.